Amprius (AMPX) Q2 2026 Earnings Call Transcript

Amprius Technologies reported Q2 revenue of $34.0M, up 19% QoQ and +126% YoY, alongside gross margin expansion to 27% (from 20% in Q1), as SiCore drove 98% of sales. The company narrowed GAAP net loss to $5.1M (includes a $1.9M non-cash warrant-modification impact) and improved adjusted EBITDA to -$1.0M. Management raised full-year 2026 guidance to at least $140M revenue and 28%+ gross margin, with adjusted EBITDA guidance of $4.0M+, supported by a $24M new European drone order for deliveries through Q1’27 and an $18.1M Defense Innovation Unit funding award. Cash increased to $74.5M at quarter-end with no debt, and liquidity/ramp visibility improved despite caution that margins could be lumpy depending on regional/product mix and defense-budget timing.

Analysis

AMPX is turning itself into a constrained-capacity supplier to an area where buyers care more about flight-time delta than unit cost, which means the economics are increasingly tied to qualification status and reliability rather than just battery commoditization. The second-order winner is any OEM or pack integrator that can use a differentiated cell to improve payload/range and win procurement tests; the losers are lower-spec Asian cell vendors and drone assemblers that cannot meet U.S./NDAA sourcing screens without redesigning their stack. RDW can benefit indirectly if better batteries improve its drone systems’ competitive win rate, but the larger value accrues to the cell supplier that becomes “sticky” once embedded.

The near-term catalyst path is mostly execution, not TAM. The next 1-3 months matter for evidence that the margin step-up is real after mix effects, tariffs, and one-time items wash out; the next 6-18 months are about whether U.S./NDAA capacity and supplier qualification actually convert into repeatable volume. The key falsifiers are a Q3/Q4 gross-margin giveback, a delay in domestic cell qualification, or receivables that stop converting to cash as the backlog gets longer and the mix becomes less favorable. Defense budget timing is a real lag risk: even if appropriations improve, flow-through to AMPX can slip by quarters.

The contrarian issue is that the market may be underwriting a straight-line ramp into 2027 before the company has proven it can scale without margin volatility. Management’s optionality in robotics/data centers is interesting but not investable today; the stock is really a bet on defense drones plus manufacturing orchestration. That argues for paying for upside convexity, not chasing common after a good print. If the business truly clears sustained positive adjusted EBITDA and holds margins while shifting more U.S.-compliant supply, the multiple can expand; if not, this stays a story stock with execution risk.

Key Decisions for Investors

• Initiate a tactical long in AMPX only on post-earnings weakness; prefer 3-6 month call spreads over outright equity to express upside from U.S./NDAA qualification while capping downside if margin guidance proves too optimistic.
• Use Q3/Q4 as the verification window: stay long AMPX only if gross margin holds at or above the raised guide and operating cash conversion remains positive after working-capital noise. Falsify the thesis if margins re-decline or receivables keep expanding into year-end.
• Do not chase RDW on the headline; keep it on watch as a second-order beneficiary. Add only if its drone-related order flow visibly improves alongside AMPX cell adoption, otherwise the linkage remains too indirect.
• Take profits into any 1-2 day post-call squeeze in AMPX; the market is likely to overpay for 2027 optionality before the company proves that domestic capacity and customer conversion are durable.